Cognition Therapeutics (CGTX) Non-Current Assets (2020 - 2026)
Cognition Therapeutics (CGTX) posted quarterly Non-Current Assets of $326000.0 for Q1 2026, down 48.58% year-over-year from $634000.0 in Q1 2025, and down 18.3% quarter-over-quarter from $399000.0 in Q4 2025.
Cognition Therapeutics (CGTX) Non-Current Assets (2020 - 2026) Analysis & Trends
Cognition Therapeutics (CGTX) has reported Non-Current Assets for 7 consecutive years, with $326000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 48.58% year-over-year to $326000.0; the TTM figure through Mar 2026 stood at $1.8 million (down 37.17% YoY), while the FY2025 annual figure was $399000.0, down 41.24% from the prior year.
- Non-Current Assets slipped to $326000.0 in Q1 2026 per CGTX's latest filing, from $399000.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $2.9 million in Q1 2023 and bottomed at $326000.0 in Q1 2026.
- Historically, Non-Current Assets has averaged $1.4 million across 5 years, with a median of $883000.0 in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Assets jumped 1815.86% — and 2024, when it tumbled 72.58%.
- Cognition Therapeutics' Non-Current Assets stood at $2.8 million in 2022, then slumped by 66.13% to $941000.0 in 2023, then decreased by 27.84% to $679000.0 in 2024, then slumped by 41.24% to $399000.0 in 2025, then declined by 18.3% to $326000.0 in 2026.
- Business Quant data shows CGTX's Non-Current Assets at $326000.0 in Q1 2026, $399000.0 in Q4 2025, and $512000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Cognition Therapeutics | 90.18 Mn | 90.18 Mn | - | 597,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 597,000.00 |
| Mar 31, 2026 | 326,000.00 |
| Dec 31, 2025 | 399,000.00 |
| Sep 30, 2025 | 512,000.00 |
| Jun 30, 2025 | 573,000.00 |
| Mar 31, 2025 | 634,000.00 |
| Dec 31, 2024 | 679,000.00 |
| Sep 30, 2024 | 749,000.00 |
| Jun 30, 2024 | 819,000.00 |
| Mar 31, 2024 | 883,000.00 |
| Dec 31, 2023 | 941,000.00 |
| Sep 30, 2023 | 2.73 Mn |
| Jun 30, 2023 | 2.41 Mn |
| Mar 31, 2023 | 2.86 Mn |
| Dec 31, 2022 | 2.78 Mn |
| Sep 30, 2022 | 2.63 Mn |
| Jun 30, 2022 | 2.07 Mn |
| Mar 31, 2022 | 2.26 Mn |
| Dec 31, 2021 | 145,000.00 |
| Sep 30, 2021 | 3.35 Mn |